ArticleAnnals of surgical oncology2026
Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Preoperative Clues to Complex Surgery After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe role of neoadjuvant chemoimmunotherapy in clinically node-negative (cN0) non-small cell lung cancer (NSCLC) remains unclear. This study aimed to evaluate perioperative outcomes and pathological response in patients with cN0.
methodsThis was a pre-specified secondary analysis of the CReGYT-04 Neo-Venus registry, a nationwide multicenter retrospective study in Japan. A total of 129 patients with stage IIA-IIIB NSCLC who received neoadjuvant nivolumab plus platinum-doublet chemotherapy were included. Patients were stratified by clinical nodal status (cN0 vs. cN1-2), and clinical characteristics, perioperative outcomes, and pathological responses were compared.
resultsThe analysis included 31 patients with cN0 and 98 with cN1-2. Preoperative treatment discontinuation was more frequent in the cN0 group (22.6% vs. 9.2%), primarily due to immune-related adverse events (irAEs) or disease progression. The surgical cancellation rate was 6.5% in the cN0 group and 9.2% in the cN1-2 group. Postoperative outcomes, including complication rates and hospital stay, were comparable between the groups, with no 30-day mortality observed in the cN0 group. Pathological complete response was achieved in 34.5% of the cN0 group and 36.1% of the cN1-2 group; major pathological response was observed in 48.3% and 62.7%, respectively. R0 resection was achieved in all cN0 patients.
conclusionsIn patients with resectable cN0 NSCLC, nivolumab-based neoadjuvant chemoimmunotherapy was associated with perioperative outcomes and pCR rates similar to those observed in patients with cN1-2. These findings suggest that this regimen may represent a treatment option for patients with cN0, with careful attention to irAEs and disease progression.
Indexed as
Identifiers
42734698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.